Ten years of anti-vascular endothelial growth factor therapy

Nature Reviews Drug Discovery

Volumn 15, Issue 6, 2016, Pages 385-403

  Ferrara, Napoleone ^a   Adamis, Anthony P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; PEGAPTANIB; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; MONOCLONAL ANTIBODY; VEGFA PROTEIN, HUMAN;

BLOOD VESSEL PERMEABILITY; DRUG APPROVAL; DRUG RESEARCH; DRUG TARGETING; DRUG USE; EYE DISEASE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTATIC COLORECTAL CANCER; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOLOGY; OPHTHALMOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; VEGFA GENE; ANTAGONISTS AND INHIBITORS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTOR; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84954569855     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.17     Document Type: Review

References (279)

1. Folkman, J., & Klagsbrun, M. Angiogenic factors. Science 235, 442-447 (1987
2. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803 (2002
3. Ide, A. G., Baker, N. H., & Warren, S. L. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 42, 891-899 (1939
4. Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl Cancer Inst. 6, 73-85 (1945
5. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971
6. Klagsbrun, M., & D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol. 53, 217-239 (1991
7. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989
8. Keck, P. J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312 (1989
9. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004
10. Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat. Med. 16, 1107-1111 (2010
11. Kim, K. J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841-844 (1993
12. Hurwitz, H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004
13. Adamis, A. P., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445-450 (1994
14. Aiello, L. P., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med. 331, 1480-1487 (1994
15. Adamis, A. P., et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66-71 (1996
16. Aiello, L. P., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad.Sci. USA 92, 10457-10461 (1995
17. Ng, E. W., et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123-132 (2006
18. Chen, Y., et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865-881 (1999
19. Motzer, R. J., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006
20. Escudier, B., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009
21. Holash, J., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393-11398 (2002
22. Krupitskaya, Y., & Wakelee, H. A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR 2 for the potential treatment of cancer. Curr. Opin. Investig. Drugs 10, 597-605 (2009
23. Senger, D. R., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983
24. Senger, D. R., Connolly, D. T., Van De Water, L., Feder, J., & Dvorak, H. F. Purification and NH2 terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50, 1774-1778 (1990
25. Ferrara, N., & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858 (1989
26. Connolly, D. T., et al. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem. 264, 20017-20024 (1989
27. Olsson, A. K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. VEGF receptor signalling -in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371 (2006
28. Alitalo, K., Tammela, T., & Petrova, T. V. Lymphangiogenesis in development and human disease. Nature 438, 946-953 (2005
29. Ferrara, N., Gerber, H. P., & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669-676 (2003
30. Neufeld, G., Cohen, T., Gengrinovitch, S., & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22 (1999
31. Ferrara, N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21, 687-690 (2010
32. Bates, D. O., et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123-4131 (2002
33. Eswarappa, S. M., et al. Programmed translational readthrough generates antiangiogenic VEGF Ax. Cell 157, 1605-1618 (2014
34. Semenza, G. L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 54, 17-28 (2003
35. Kaelin, W. G. Jr The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865-873 (2008
36. Jakeman, L. B., Winer, J., Bennett, G. L., Altar, C. A., & Ferrara, N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 89, 244-253 (1992
37. De Vries, C., et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991 (1992
38. Terman, B. I., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579-1586 (1992
39. Pajusola, K., et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res. 52, 5738-5473 (1992
40. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. Neuropilin 1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745 (1998
41. Park, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt 1 but not to Flk 1/KDR. J. Biol. Chem. 269, 25646-25654 (1994
42. Davis-Smyth, T., Chen, H., Park, J., Presta, L. G., & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt 1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919-4927 (1996
43. Ambati, B. K., et al. Corneal avascularity is due to soluble VEGF receptor 1. Nature 443, 993-997 (2006
44. Herbert, S. P., & Stainier, D. Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551-564 (2011
45. Carmeliet, P., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996
46. Ferrara, N., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996
47. Shalaby, F., et al. Failure of blood-island formation and vasculogenesis in Flk 1 deficient mice. Nature 376, 62-66 (1995
48. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N., & Shibuya, M. Essential role of Flk 1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl Acad. Sci. USA 102, 1076-1081 (2005
49. Fukumura, D., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl Acad. Sci. USA 98, 2604-2609 (2001
50. Eliceiri, B. P., et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915-924 (1999
51. Gavard, J., & Gutkind, J. S. VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE cadherin. Nat. Cell Biol. 8, 1223-1234 (2006
52. Sun, Z., et al. VEGFR2 induces c Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J. Exp. Med. 209, 1363-1377 (2012
53. Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003
54. Nagy, J. A., Chang, S. H., Dvorak, A. M., & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100, 865-869 (2009
55. Tolentino, M. J., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103, 1820-1828 (1996
56. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008
57. Kowanetz, M., & Ferrara, N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12, 5018-5022 (2006
58. Ellis, L. M., & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008
59. Kim, K. J., Li, B., Houck, K., Winer, J., & Ferrara, N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53-64 (1992
60. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., & Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789-1797 (1995
61. Borgstrom, P., Hillan, K. J. Sriramarao, P., & Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56, 4032-4039 (1996
62. Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A., & Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253-6258 (2000
63. Liang, W. C., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006
64. Shima, D. T., et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest. Ophthalmol. Vis. Sci. 37, 1334-1340 (1996
65. Presta, L. G., et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997
66. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986
67. Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004
68. Gordon, M. S., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850 (2001
69. Ferrara, N., Mass, R. D., Campa, C., & Kim, R. Targeting VEGF A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 58, 491-504 (2007
70. Margolin, K., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19, 851-856 (2001
71. Ferrara, N., & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005
72. Scappaticci, F. A., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99, 1232-1239 (2007
73. Klement, G., et al. Continuous low-dose therapy with vinblastine and VEGF receptor 2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000
74. Sweeney, C. J., et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2 methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61, 3369-3372 (2001
75. Gerber, H. P., & Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680 (2005
76. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005
77. Willett, C. G., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004
78. Kabbinavar, F., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60-65 (2003
79. Giantonio, B. J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007
80. Bennouna, J., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 14, 29-37 (2013
81. Sandler, A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006
82. Yang, J. C., et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003
83. Rini, B. I., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008
84. Escudier, B., et al. Phase III trial of bevacizumab plus interferon alfa 2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010
85. Friedman, H. S., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009
86. Kreisl, T. N., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009
87. Chinot, O. L., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014
88. Gilbert, M. R., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014
89. Tewari, K. S., et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734-743 (2014
90. Pujade-Lauraine, E., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized Phase III trial. J. Clin. Oncol. 32, 1302-1308 (2014
91. Aghajanian, C., et al. OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039-2045 (2012
92. Burger, R. A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483 (2011
93. Plotkin, S. R., et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358-367 (2009
94. Miller, K., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007
95. Brufsky, A. M., et al. RIBBON 2: a randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2 negative metastatic breast cancer. J. Clin. Oncol. 29, 4286-4293 (2011
96. Robert, N. J., et al. RIBBON 1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2 negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260 (2011
97. Miles, D. W., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2 negative metastatic breast cancer. J. Clin. Oncol. 28, 3239-3247 (2010
98. Meadows, K. L., & Hurwitz, H. I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2, a006577 (2012
99. Allegra, C. J., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11-16 (2011
100. Allegra, C. J., et al. Bevacizumab in stage II III colon cancer: 5 year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359-364 (2013
101. De Gramont, A., et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial. Lancet Oncol. 13, 1225-1233 (2012
102. Dienstmann, R., Salazar, R., & Tabernero, J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J. Clin. Oncol. 33, 1787-1796 (2015
103. Gschwind, A., Fischer, O. M., & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361-370 (2004
104. Strawn, L. M., et al. Flk 1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-3545 (1996
105. Levitzki, A., & Mishani, E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 75, 93-109 (2006
106. McTigue, M. A., et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7, 319-330 (1999
107. Levitzki, A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. Rev. Pharmacol. Toxicol. 53, 161-185 (2013
108. Manley, P. W., Martiny-Baron, G., Schlaeppi, J. M., & Wood, J. M. Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs 11, 1715-1736 (2002
109. Wilhelm, S. M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
110. Strumberg, D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 41, 773-784 (2005
111. Escudier, B., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007
112. Llovet, J. M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008
113. Brose, M. S., et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 3 trial. Lancet 384, 319-328 (2014
114. Haraldsdottir, S., & Shah, M. H. An update on clinical trials of targeted therapies in thyroid cancer. Curr. Opin. Oncol. 26, 36-44 (2014
115. Mendel, D. B., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003
116. Faivre, S., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-35 (2006
117. Motzer, R. J., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007
118. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003
119. Raymond, E., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011
120. Sternberg, C. N., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010
121. Motzer, R. J., McCann, L., & Deen, K. Pazopanib versus sunitinib in renal cancer. N. Engl. J. Med. 369, 1970 (2013
122. Hu Lowe, D. D., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG 013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14, 7272-7283 (2008
123. Rini, B. I., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378, 1931-1939 (2011
124. Wilhelm, S. M., et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245-255 (2011
125. Grothey, A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381, 303-312 (2013
126. Robert, N. J., et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a Phase III, randomized, open-label trial. Clin. Breast Cancer 11, 82-92 (2011
127. Bergh, J., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized Phase III study. J. Clin. Oncol. 30, 921-929 (2012
128. Carrato, A., et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, Phase III trial. J. Clin. Oncol. 31, 1341-1347 (2013
129. Schmoll, H. J., et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized Phase III study (HORIZON III). J. Clin. Oncol. 30, 3588-3595 (2012
130. Ebos, J. M., et al. Accelerated metastasis after short term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009
131. Blagoev, K. B., et al. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep. 3, 277-281 (2013
132. Hilberg, F., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782 (2008
133. Reck, M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a Phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143-155 (2014
134. Richeldi, L., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071-2082 (2014
135. Van Cutsem, E., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499-3506 (2012
136. Tang, P. A., & Moore, M. J. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap. Adv. Gastroenterol. 6, 459-473 (2013
137. De Groot, J. F., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 29, 2689-2695 (2011
138. Ramlau, R., et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled Phase III trial. J. Clin. Oncol. 30, 3640-3647 (2012
139. Clarke, J. M., & Hurwitz, H. I. Ziv-aflibercept: binding to more than VEGF A -does more matter? Nat. Rev. Clin. Oncol. 10, 10-11 (2013
140. Fischer, C., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007
141. Bais, C., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141, 166-177 (2010
142. Fuchs, C. S., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo controlled, Phase 3 trial. Lancet 383, 31-39 (2013
143. Wilke, H., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase 3 trial. Lancet Oncol. 15, 1224-1235 (2014
144. Garon, E. B., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised Phase 3 trial. Lancet 384, 665-673 (2014
145. Tabernero, J., et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, Phase 3 study. Lancet Oncol. 16, 499-508 (2015
146. Motzer, R. J., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008
147. Sennino, B., & McDonald, D. M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 12, 699-709 (2012
148. Lu, K. V., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35 (2012
149. Cloughesy, T., et al. Onartuzumab plus bevacizumab versus placebo in recurrent glioblastoma (GBM): HGF and MGMT biomarker data. Proc. Am. Soc. Clin. Oncol. 33, 2015 (2015
150. Charakidis, M., & Boyer, M. Targeting MET and EGFR in NSCLC -what can we learn from the recently reported Phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Transl. Lung Cancer Res. 3, 395-396 (2014
151. Lassen, U., et al. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 17, 1007-1015 (2015
152. Snuderl, M., et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152, 1065-1076 (2013
153. Augustin, H. G., Koh, G. Y., Thurston, G., & Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10, 165-177 (2009
154. Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 10, 575-585 (2010
155. Rigamonti, N., et al. Role of angiopoietin 2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 8, 696-706 (2014
156. Liang, W. C., et al. Function blocking antibodies to neuropilin 1 generated from a designed human synthetic antibody phage library. J. Mol. Biol. 366, 815-829 (2007
157. Johnson, L., et al. Anti EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J. Clin. Invest. 123, 3997-4009 (2013
158. Ince, W. L., et al. Association of k RAS, b RAF, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst. 97, 981-989 (2005
159. Hegde, P. S., et al. Predictive impact of circulating vascular endothelial growth factor in four Phase III trials evaluating bevacizumab. Clin. Cancer Res. 19, 929-937 (2013
160. Rini, B. I., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 103, 763-773 (2011
161. Jubb, A. M., & Harris, A. L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 11, 1172-1183 (2010
162. Secord, A. A., Nixon, A. B., & Hurwitz, H. I. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. Gynecol. Oncol. 135, 349-358 (2014
163. Hanrahan, E. O., et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 28, 193-201 (2010
164. Xu, L., et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 69, 7905-7910 (2009
165. Jain, R. K., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009
166. Brauer, M. J., et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin. Cancer Res. 19, 3681-3692 (2013
167. De Haas, S., et al. Genetic variability of VEGF pathway genes in six randomized Phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 17, 909-920 (2014
168. Dellian, M., Witwer, B. P., Salehi, H. A., Yuan, F., & Jain, R. K. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment [see comments]. Am. J. Pathol. 149, 59-71 (1996
169. Sandmann, T., et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J. Clin. Oncol. (2015
170. Wagle, N., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011
171. Chung, A. S., Lee, J., & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505-514 (2010
172. Shojaei, F., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotech. 25, 911-920 (2007
173. Shojaei, F., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007
174. Finke, J., et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856-861 (2011
175. Ferrara, N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 21, 21-26 (2010
176. Paez-Ribes, M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009
177. Singh, M., et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J. Pathol. 227, 417-430 (2012
178. Chung, A. S., et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J. Pathol. 227, 404-416 (2012
179. Bill, R., et al. Nintedanib is a highly effective therapeutic for neuroendocrine carcinoma of the pancreas (PNET) in the Rip1Tag2 transgenic mouse model. Clin. Cancer Res. 21, 4856-4865 (2015
180. Miles, D., et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized Phase III trials. J. Clin. Oncol. 29, 83-88 (2011
181. Singh, M., & Ferrara, N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat. Biotech. 30, 648-657 (2012
182. Garner, A. in Pathobiology of Ocular Disease (eds Garner, A., & Klintworth, G. K.) 1625-1710 (Marcel Dekker, 1994
183. Michaelson, I. C. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans. Ophthalmol. Soc. UK 68, 137-180 (1948
184. Ashton, N. Observations on the choroidal circulation. Br. J. Ophthalmol. 36, 465-481 (1952
185. Wise, G. N. Retinal neovascularization. Trans. Am. Ophthalmol. Soc. 54, 729-826 (1956
186. Adamis, A. P., et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 193, 631-638 (1993
187. Miller, J. W., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145, 574-584 (1994
188. Malecaze, F., et al. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112, 1476-1482 (1994
189. Tolentino, M. J., et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch. Ophthalmol. 114, 964-970 (1996
190. Schwesinger, C., et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am. J. Pathol. 158, 1161-1172 (2001
191. Krzystolik, M. G., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338-346 (2002
192. Qaum, T., et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42, 2408-2413 (2001
193. Miller, J. W., Le Couter, J., Strauss, E. C., & Ferrara, N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology 120, 106-114 (2013
194. Gragoudas, E. S., et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816 (2004
195. Ryan, A. M., et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27, 78-86 (1999
196. Hodge, W. G., Lalonde, R. G., Sampalis, J., & Deschenes, J. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J. Infect. Dis. 174, 393-396 (1996
197. Ferrara, N., Damico, L., Shams, N., Lowman, H., & Kim, R. Developmemt of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859-870 (2006
198. Mordenti, J., et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. 27, 536-544 (1999
199. Raghavan, M., & Bjorkman, P. J. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12, 181-220 (1996
200. Reff, M. E., Hariharan, K., & Braslawsky, G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 9, 152-166 (2002
201. Nieminen, T., et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand. J. Clin. Lab Invest. 67, 237-245 (2007
202. Baca, M., Presta, L. G., O'Connor, S. J., & Wells, J. A. Antibody humanization using monovalent phage display. J. Biol. Chem. 272, 10678-10684 (1997
203. Muller, Y. A., et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 a resolution and mutational analysis of the interface. Structure 6, 1153-1167 (1998
204. Gaudreault, J., Fei, D., Rusit, J., Suboc, P., & Shiu, V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726-733 (2005
205. Rosenfeld, P. J., et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112, 1048-1053 (2005
206. Heier, J. S., et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Opthalmology 113, 633-642.e4 (2006
207. Rosenfeld, P. J., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006
208. Brown, D. M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006
209. Brown, D. M., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116, 57-65.e5 (2009
210. Frennesson, C., Nilsson, U. L., Peebo, B. B., & Nilsson, S. E. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmol. 88, 420-425 (2010
211. Regillo, C. D., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am. J. Ophthalmol. 145, 239-248 (2008
212. Schmidt-Erfurth, U., et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118, 831-839 (2011
213. Busbee, B. G., et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120, 1046-1056 (2013
214. Abedi, F., Wickremasinghe, S., Islam, A. F., Inglis, K. M., & Guymer, R. H. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 34, 1531-1538 (2014
215. Bressler, N. M., et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch. Ophthalmol. 129, 709-717 (2011
216. Brown, D. M., et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117, 1124-1133.e1 (2010
217. Campochiaro, P. A., et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117, 1102-1112.e1 (2010
218. Nguyen, Q. D., et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology 119, 789-801 (2012
219. Diabetic Retinopathy Clinical Research Network., et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 118, e5-e14 (2011
220. Varma, R., et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119, 2108-2118 (2012
221. Brown, D. M., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36 month results from two Phase III trials: RISE and RIDE. Ophthalmology 120, 2013-2022 (2013
222. Bressler, N. M., et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology 121, 2461-2472 (2014
223. Campochiaro, P. A., et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121, 209-219 (2014
224. Elman, M. J., et al. Expanded 2 year follow up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118, 609-614 (2011
225. Diabetic Retinopathy Clinical Research Network., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119, 2312-2318 (2012
226. Diabetic Retinopathy Clinical Research Network., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117, 1064-1077.e35 (2010
227. Campochiaro, P. A., et al. Monthly versus as needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 121, 2432-2442 (2014
228. Group, C. R., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897-1908 (2011
229. IVAN Study Investigators, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119, 1399-1411 (2012
230. Avery, R. L., et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 98, 1636-1641 (2014
231. Heier, J. S., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537-2548 (2012
232. Diabetic Retinopathy Clinical Research Network., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med. 372, 1193-1203 (2015
233. Pecen, P. E., & Kaiser, P. K. Current Phase 1/2 research for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 26, 188-193 (2015
234. Holz, F. G., et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 99, 220-226 (2015
235. Jo, N., et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 168, 2036-2053 (2006
236. Boyer, D. S. Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeration (NV AMD) -results of a Phase I study. Invest. Ophthalmol. Vis. Sci. 50, 1260 (2009
237. Boyer, D. S. A Phase 2b study of FovistaTM, a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor for neovascular age-related macular degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 54, 2175 (2013
238. Jager, R. D., Mieler, W. F., & Miller, J. W. Age-related macular degeneration. N. Engl. J. Med. 358, 2606-2617 (2008
239. Nishijima, K., et al. Vascular endothelial growth factor A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53-67 (2007
240. Comparison of Age-related Macular Degeneration Treatments Trials Research Group., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119, 1388-1398 (2012
241. Miki, A., et al. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J. Cell. Physiol. 224, 262-272 (2010
242. Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997
243. Ho, A. C., et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121, 2181-2192 (2014
244. Bloch, S. B., Larsen, M., Munch, I. G. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am. J. Ophthalmol. 153, 209-213 (2012
245. Shrimali, R. K., et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010
246. Liu, J. F., et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised Phase 2 study. Lancet Oncol. 15, 1207-1214 (2014
247. Schmidt-Erfurth, U., et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br. J. Ophthalmol. 98, 1144-1167 (2014
248. Wong, W. L., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2, e106-e116 (2014
249. Ferris, F. L. 3rd, Fine, S. L., & Hyman, L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 102, 1640-1642 (1984
250. Friedman, D. S., et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572 (2004
251. Yau, J. W., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35, 556-564 (2012
252. Chen, E., et al. Burden of illness of diabetic macular edema: literature review. Curr. Med. Res. Opin. 26, 1587-1597 (2010
253. Rogers, S., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117, 313-319.e1 (2010
254. Borooah, S., et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond.) 29, 1156-1161 (2015
255. Mitchell, P., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118, 615-625 (2011
256. Chakravarthy, U., et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113, 1508.e1-1508.e25 (2006
257. Brown, D. M., et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1 year results from the Phase 3 COPERNICUS study. Am. J. Ophthalmol. 155, 429-437.e7 (2013
258. Holz, F. G., et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6 month results of the Phase III GALILEO study. Br. J. Ophthalmol. 97, 278-284 (2013
259. Korobelnik, J. F., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121, 2247-2254 (2014
260. Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P., & Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl Acad. Sci. USA 88, 9267-9271 (1991
261. Olofsson, B., et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 93, 2576-2581 (1996
262. Joukov, V., et al. A novel vascular endothelial growth factor, VEGF C, is a ligand for the Flt4 (VEGFR 3) and KDR (VEGFR 2) receptor tyrosine kinases. EMBO J. 15, 290-298 (1996
263. Orlandini, M., Marconcini, L., Ferruzzi, R., & Oliviero, S. Identification of a c FOS-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl Acad. Sci. USA 93, 11675-11680 (1996); erratum 94, 1603 (1997
264. Shibuya, M., et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 8, 519-527 (1990
265. Terman, B. I., et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 1677-1683 (1991
266. Shweiki, D., Itin, A., Soffer, D., & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992
267. Plate, K. H., Breier, G., Weich, H. A., & Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992
268. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk 1 mutant. Nature 367, 576-579 (1994
269. Fong, G. H., Rossant, J., Gertsenstein, M., & Breitman, M. L. Role of the Flt 1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995
270. Cobleigh, M. A., et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117-124 (2003
271. Motzer, R. J., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006
272. Demetri, G. D., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338 (2006
273. Escudier, B., et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa 2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280-1289 (2009
274. Caunt, M., et al. Blocking neuropilin 2 function inhibits tumor cell metastasis. Cancer Cell 13, 331-342 (2008
275. LeCouter, J., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR 1. Science 299, 890-893 (2003
276. Yao, J., et al. Expression of a functional VEGFR 1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc. Natl Acad. Sci. USA 108, 11590-11595 (2011
277. Reck, M., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAiL). Ann. Oncol. 21, 1804-1809 (2010
278. Motzer, R. J., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009
279. Escudier, B., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009